Objective: To study the effect of Betaloc in clinical intervention of uremic hemodialysis patients with heart failure. Methods: 76 patients with uremic hemodialysis complicated with heart failure received in our hospital from February 2020 to September 2021 were randomly divided into two groups. The patients in the control group received benazepril treatment intervention,and the patients in the observation group were treated with betaloc on the basis of benazepril. The clinical efficacy differences of different treatment methods were evaluated. Results: The cardiac function indexes of the two groups were compared. The left ventricular ejection fraction (LVEF) of the observation group was higher than that of the control group,and the diastolic diameter (LVEDd) was lower than that of the control group. There was significant difference between the two groups (P < 0.05) The serum BNP in the observation group was lower than that in the control group (P < 0.05),and the 6-minute walking distance in the observation group was higher than that in the control group (P < 0.05). The results of drug safety evaluation showed that there was no significant difference between the groups (P > 0.05). Conclusion: Betaloc has significant clinical advantages in the clinical treatment of uremic hemodialysis patients with heart failure. It can further improve patients’ cardiac function and eliminate many adverse symptoms of heart failure,which is worthy of promotion.

目的 探讨维持性血液透析患者透析过程中发生低血压的影响因素及证候特征.方法 选取2021年4月-2021年6月于费森尤斯连锁透析中心行维持性血液透析的患者210例,根据透析期间是否发生低血压分为观察组(有低血压者42例)和对照组(无低血压者168例)进行横断面研究.分析2组患者性别、年龄、BMI、是否合并糖尿病或冠心病、血流量、平均透析间期体重增长率、超滤率、透析前血红蛋白、血清白蛋白水平、血尿素、PTH、肾素的差异性.并采用多因素Logistic回归分析透析中低血压的独立影响因素.同时进行四诊合参,采用中医证候调查表,对观察组患者的中医证候特征进行总结分析.结果 维持性血液透析患者透析过程中发生低血压的独立危险因素为年龄、冠心病、贫血.血液透析低血压患者在中医证型分布上以脾肾阳虚,脾肾气虚、湿热证、血瘀证为主.结论 维持性血液透析过程中应对高龄、合并糖尿病冠心病、贫血以及中医证型为脾肾阳虚,脾肾气虚、湿热证、血瘀证的患者加强监测,采用相关预防措施,降低低血压发生率.